Behavioral and psychiatric adverse events associated with antiepileptic drugs commonly used in pediatric patients

Journal of Child Neurology

Volumn 19, Issue SUPPL. 1, 2004, Pages

  Glauser, Tracy A ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; DIAZEPAM; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; PRIMIDONE; SULTIAME; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

AGGRESSIVENESS; ANGER; ANOREXIA; ANTICONVULSANT ACTIVITY; ANTISOCIAL BEHAVIOR; ANXIETY DISORDER; APATHY; ATTENTION DEFICIT DISORDER; AUDITORY HALLUCINATION; BEHAVIOR DISORDER; BODY WEIGHT DISORDER; CHILD; CHILD HEALTH CARE; CLINICAL TRIAL; CONCENTRATION LOSS; CONFUSION; DELIRIUM; DELUSIONAL DISORDER; DEPRESSION; DEVELOPMENTAL DISORDER; DROWSINESS; DRUG DOSE REGIMEN; DRUG MECHANISM; EMOTIONAL DISORDER; ENZYME INHIBITION; EPILEPSY; FATIGUE; FEBRILE CONVULSION; GABAERGIC TRANSMISSION; HALLUCINOSIS; HOSTILITY; HUMAN; HYPERACTIVITY; HYPERKINESIA; IMPULSIVENESS; INCIDENCE; INSOMNIA; IRRITABILITY; LEARNING DISORDER; LETHARGY; MAJOR DEPRESSION; MANIA; MENTAL DEFICIENCY; MENTAL DISEASE; MENTAL INSTABILITY; METHODOLOGY; MONOTHERAPY; MOOD DISORDER; NERVOUSNESS; NEUROLOGIC DISEASE; NIGHTMARE; PARANOIA; PERSONALITY DISORDER; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; RESTLESSNESS; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUICIDE ATTEMPT; THOUGHT DISORDER;

EID: 8344274386     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/088307380401900104     Document Type: Review

References (83)

1. IMS Health's National Disease and Therapeutic Index (NDTI) Audit with Data on a Moving Annual Total Basis for the 12-Month Period Ending in December 2003. See: www.imshealth.com.
2. Rho JM, Sankar R: The pharmacologic basis of antiepileptic drug action. Epilepsia 1999;40:1471-1483.
3. Stefani A, Spadoni F, Bernardi G: Voltage-activated calcium Channels: Targets of antiepileptic drug therapy? Epilepsia 1997; 38: 959-965.
4. Klitgaard H: Levetiracetam: The preclinical profile of a new class of antiepileptic drugs? Epilepsia 2001;42(Suppl 4):13-18.
5. Mula M, Trimble MR, Lhatoo, SD, Sander JW: Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 2003;44:659-663.
6. Mula M, Trimble MR, Yuen A, et al: Psychiatric adverse events during levetiracetam therapy. Neurology 2003;61:704-706.
7. Dodrill CB, Troupin AS: Psychotropic effects of carbamazepine in epilepsy: A double-blind comparison with phenytoin. Neurology 1977;27:1023-1028.
8. Khurana DS, Riviello J, Helmers S, et al: Efficacy of gabapentin therapy in children with refractory partial seizures. J Pediatr 1996;128:829-833.
9. Kanner AM, Wuu J, Faught E, et al, and the PADS Investigators. A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 2003;4:548-552.
10. Devinsky O: Cognitive and behavioral effects of antiepileptic drugs. Epilepsia 1995;36(Suppl 2):S46-S65.
11. Kwan P, Brodie MJ: Neuropsychological effects of epilepsy and antiepileptic drugs. Lancet 2001;357:216-222.
12. Herranz JL, Armijo JA, Arteaga R: Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy in children. Epilepsia 1988;29:794-804.
13. Wolf SM, Carr A, Davis DC, et al: The value of phenobarbital in the child who has had a single febrile seizure: A controlled prospective study. Pediatrics 1977;59:378-385.
14. Wolf SM, Forsythe A: Behavior disturbance, phenobarbital, and febrile seizures. Pediatrics 1978;61:728-731.
15. Knudsen FU, Vestermark S: Prophylactic diazepam or phenobarbitone in febrile convulsions: A prospective, controlled study. Arch Dis Child 1978;53:660-663.
16. Domizio S, Verrotti A, Ramenghi LA, et al: Anti-epileptic therapy and behaviour disturbances in children. Childs Nerv Syst 1993;9: 272-274.
17. Thilothammal N, Banu K, Ratnam RS: Comparison of phenobarbitone, phenytoin with sodium valproate: Randomized, double-blind study. Indian Pediatr 1996;33:549-555.
18. Camfield CS, Chaplin S, Doyle AB, et al: Side effects of phenobarbital in toddlers; behavioral and cognitive aspects. J Pediatr 1979;95:361-365.
19. Antony JH, Hawke SH: Phenobarbital compared with carbamazepine in prevention of recurrent febrile convulsions. A double-blind study. Am J Dis Child 1983; 137:892-895.
20. Hellstrom B, Barlach-Christoffersen M: Influence of phenobarbital on the psychomotor development and behaviour in preschool children with convulsions. Neuropadiatrie 1980;11:151-160.
21. Willis J, Nelson A, Black FW, et al: Barbiturate anticonvulsants: A neuropsychological and quantitative electroencephalographic study. J Child Neurol 1997;12:169-171.
22. de Silva M, MacArdle B, McGowan M, et al: Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996;347:709-713.
23. Pal DK, Das T, Chaudhury G, et al: Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet 1998;351:19-23.
24. Herranz JL, Armijo JA, Arteaga R: Effectiveness and toxicity of phenobarbital, primidone, and sodium valproate in the prevention of febrile convulsions, controlled by plasma levels. Epilepsia 1984;25:89-95.
25. Mamelle N, Mamelle JC, Plasse JC, et al: Prevention of recurrent febrile convulsions - A randomized therapeutic assay: Sodium valproate, phenobarbital and placebo. Neuropediatrics 1984; 15: 37-42.
26. Brent DA, Crumrine PK, Varma RR, et al: Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics 1987;80:909-917.
27. Brent DA, Crumrine PK, Varma R, et al: Phenobarbital treatment and major depressive disorder in children with epilepsy: A naturalistic follow-up. Pediatrics 1990;85:1086-1091.
28. Appleton R, Fichtner K, LaMoreaux L, et al, and the Gabapentin Paediatric Study Group: Gabapentin as add-on therapy in children with refractory partial seizures: A 12-week, multicentre, doubleblind, placebo-controlled study. Epilepsia 1999; 40:1147-1154.
29. Appleton R, Fichtner K, LaMoreaux L, et al: Gabapentin as add-on therapy in children with refractory partial seizures: A 24-week, multicentre, open-label study. Dev Med Child Neurol 2001;43: 269-273.
30. Korn-Merker E, Borusiak P, Boenigk HE: Gabapentin in childhood epilepsy: A prospective evaluation of efficacy and safety. Epilepsy Res 2000;38:27-32.
31. Herranz JL, Arteaga R, Armijo JA: Side effects of sodium valproate in monotherapy controlled by plasma levels: A study in 88 pediatric patients. Epilepsia 1982-23:203-214.
32. Sherard ES Jr, Steiman GS, Couri D: Treatment of childhood epilepsy with valproic acid: Results of the first 100 patients in a 6-month trial. Neurology 1980;30:31-35.
33. Husain SB, Wical BS: Adverse behavioral effects of valproate therapy in children with complex partial seizures. Epilepsia 1998;39(Suppl 6):162.
34. Ohtsuka Y, Amano R, Mizukawa M, et al: Treatment of intractable childhood epilepsy with high-dose valproate. Epilepsia 1992; 33:158-164.
35. Sato S, White BG, Penry JK, et al: Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology 1982; 32:157-163.
36. Callaghan N, O'Hare J, O'Driscoll D, et al: Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Dev Med Child Neurol 1982;24: 830-836.
37. Verity CM, Hosking G, Easter DJ, for the Paediatric EPITEG Collaborative Group: A multicentre comparative trial of sodium valproate and carbamazopine in paediatric epilepsy. Dev Med Child Neurol 1995;37:97-108.
38. Silverstein FS, Parrish MA, Johnston MV. Adverse behavioral reactions in children treated with carbamazepine (Tegretol). J Pediatr 1982;101:785-787.
39. Kramer U, Shahar E, Zelnik N, et al: Carbamazepine versus sulthiame in treating benign childhood epilepsy with centrotemporal spikes. J Child Neurol 2002;17:914-916.
40. Zamponi N, Cardinali C: Open comparative long-term study of vigabatrin vs carbamazepine in newly diagnosed partial seizures in children. Arch Neurol 1999;56:605-607.
41. Eriksson AS, Nergardh A, Hoppu K: The efficacy of lamotrigine in children and adolescents with refractory generalized epilepsy: a randomized, double-blind, crossover study. Epilepsia 1998;39:495-501.
42. Farrell K, Connolly MB, Munn R, et al: Prospective, open-label, add-on study of lamotrigine in 56 children with intractable generalized epilepsy. Pediatr Neurol 1997;16:201-205.
43. Duchowny M, Pellock JM, Graf WD, et al, for the Lamictal Pediatric Partial Seizure Study Group: A placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children. Neurology 1999;53:1724-1731.
44. Duchowny M, Gilman J, Messenheimer J, et al: Long-term tolerability and efficacy of lamotrigine in pediatric patients with epilepsy. J Child Neurol 2002;17:278-285.
45. Besag FM, Wallace SJ, Dulac O, et al: Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995;127:991-997.
46. Besag FM, Dulac O, Alving J, Mullens EL: Long-term safety and efficacy of lamotrigine (Lamictal) in paediatric patients with epilepsy. Seizure 1997;6:51-56.
47. Uvebrant P, Bauziene R: Intractable epilepsy in children. The efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics 1994;25:284-289.
48. Coppola G, Pascotto A: Lamotrigine as add-on drug in children and adolescents with refractory epilepsy and mental delay: An open trial. Brain Dev 1997;19:398-402.
49. Buoni S, Grosso S, Fois A: Lamotrigine treatment in childhood drug resistant epilepsy. J Child Neurol 1998;13:163-167.
50. Caviedes BE, Herranz JL, Arteaga R, Armijo JA: In children with refractory epilepsy: Vigabatrin or lamotrigine [in Spanish]? Rev Neurol 1999;28:444-448.
51. Guerreiro MM, Vigonius U, Pohlmann H, et al: A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997;27: 205-213.
52. Glauser TA, Nigro M, Sachdeo R, et al, and the Oxcarbazepirle Pediatric Study Group: Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology 2000;54:2237-2244.
53. Serdaroglu G, Kurul S, Tutuncuoglu S, et al: Oxcarbazepine in the treatment of childhood epilepsy. Pediatr Neurol 2003;28:37-41.
54. Gaily E, Granstrom ML, Liukkonen E: Oxcarbazepine in the treatment of epilepsy in children and adolescents with intellectual disability. J Intellect Disabil Res 1998;42(Suppl 1):41-45.
55. Glauser TA, Pellock JM: Zonisamide in pediatric epilepsy: Review of the Japanese experience. J Child Neurol 2002;17:87-96.
56. Iinuma K, Minami T, Cho K, et al: Long-term effects of zonisamide in the treatment of epilepsy in children with intellectual disability. J Intellect Disabil Res 1998;42(Suppl 1):68-73.
57. Miyamoto T, Kohsaka M, Koyama T: Psychotic episodes during zonisamide treatment. Seizure 2000;9:65-70.
58. Glauser TA, Pellock JM, Bebin EM, et al: Efficacy and safety of levetiracetam in children with partial seizures: An open-label trial. Epilepsia 2002;43:518-524.
59. Wheless JW, Ng YT: Levetiracetam in refractory pediatric epilepsy. J Child Neurol 2002;17:413-415.
60. Bourgeois BFD, Holder DL, Valencia I, et al: Open-label assessment of levetiracetam efficacy and adverse effects in a pediatric population. Epilepsia 2001;42(Suppl 7):53.
61. Gustafson MC, Ritter FJ, Frost MD, et al: Clinical experience with levetiracetain treating refractory, symptomatic seizures in children. Epilepsia 2001;42(Suppl 7):55.
62. Strunc MJ, Levisohn PM: Tolerability and efficacy of levetiracetam in children. Epilepsia 2001;42(Suppl 7):92.
63. Faircloth VC, Hunt SL, Yuncker LA, Barron TF: Levetiracetam adjunctive therapy for refractory pediatric focal-onset epilepsy. Epilepsia 2001;42(Suppl 7):54.
64. Herranz JL, Rufo-Campos M, Arteaga R: Effectiveness and tolerability of levetiracetam in 43 children and adolescents with epilepsy [in Spanish]. Rev Neurol 2003;37:1005-1008.
65. Tan MJ, Appleton RE: Efficacy and tolerability of levetiracetam in children aged 10 years and younger: A clinical experience. Seizure 2004;13:142-145.
66. Eltenuarr RD, Glauser TA, Wyllie E, et al, and the Topiramate YP Study Group: A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology 1999;52:1338-1344.
67. Ritter F, Glauser TA, Elterman RD, Wyllie E, and the Topiramate YP Study Group: Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures. Epilepsia 2000; 41(Suppl 1):S82-S85.
68. Sachdeo RC, Glauser TA, Ritter F, et al, and the Topiramate YL Study Group: A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome. Neurology 1999;52:1882-1887.
69. Glauser TA, Levisohn PM, Ritter F, Sachdeo RC, and the Topiramate YL Study Group: Topiramate in Lennox-Gastaut syndrome: Open-label treatment of patients completing a randomized controlled trial. Epilepsia 2000;41(Suppl 1):S86-S90.
70. Guerreiro MM, Manreza ML, Scotom AE, et al: A pilot study of topiramate in children with Lennox-Gastaut syndrome. Arq Neuropsiquiatr 1999;57:167-175.
71. Coppola G, Caliendo G, Veggiotti P, et al: Topiramate as add-on drug in children, adolescents and young adults with Lennox-Gastaut syndrome: An Italian multicentric study. Epilepsy Res 2002;51:147-153.
72. Glauser TA, Clark PO, Strawsburg R: A pilot study of topiramate in the treatment of infantile spasms. Epilepsia 1998;39:1324-1328.
73. Glauser TA, Clark PO, McGee K: Long-term response to topiramate in patients with West syndrome. Epilepsia 2000;41(Suppl 1):S91-S94.
74. Mikaeloff Y, Saint-Martin A, Mancini J, Peudenier S, et al: Topiramate: Efficacy and tolerability in children according to epilepsy syndromes. Epilepsy Res 2003;53:225-232.
75. Moreland EC, Griesemer DA, Holden KR: Topiramate for intractable childhood epilepsy. Seizure 1999;8:38-40.
76. Uldall P, Buchholt JM: Clinical experiences with topiramate in children with intractable epilepsy. Eur J Paediatr Neurol 1999;3:105-111.
77. Thijs J, Verhelst H, Van Coster R: Retrospective study of topiramate in a paediatric population with intractable epilepsy showing promising effects in the West syndrome patients. Acta Neurol Belg 2001;1101:171-176.
78. Reith D, Burke C, Appleton DB, et al: Tolerability of topiramate in children and adolescents. J Paediatr Child Health 2003; 39:416-419.
79. Voorhies TM: Cognitive and behavioral effects of antiepileptic drugs. Semin Neurol 1988-18:35-41.
80. Pellock JM, Morton LD: Treatment of epilepsy in the multiply handicapped. Ment Retard Dev Disabil Res Rev 2000;6:309-323.
81. Gilliam FG, Fessler AJ, Baker G, et al: Systematic screening allows reduction of adverse antiepileptic drug effects: A randomized trial. Neurology 2004;62:23-27.
82. Morita DA, Glauser TA, Altaye M, et al: The Cincinnati AED Side-Effect Scale (CASE Scale): Development and validation of a tool to measure antiepileptic drug side effects objectively in children with epilepsy, abstract. Epilepsia 2003;44(Suppl 9):279.
83. Glauser TA: Advancing the medical management of epilepsy: Disease modification and pharmacogenetics. J Child Neurol 2002;17(Suppl 1):S85-S93.